DJIA 16,204.97 -211.61 -1.29%
NASDAQ 4,363.14 -146.42 -3.25%
S&P 500 1,880.05 -35.40 -1.85%
market minute promo

Geron Corp (NASDAQ: GERN)



company name or ticker

Nick's Picks 2016: Happily Overweight With Healthcare

2 Speculative Small-Cap Biotech Stocks That Could Double

These biotechs have no approved products yet, but they do have collaborations and clinical results that suggest their shares could be big winners down the road.

Geron Up, Myelodysplastic Syndromes Phase II/III Study Begins

Geron Mixed After Company Announces Start Of Phase 2/3 Clinical Trial

Johnson & Johnson's CEO Just Tipped His Cap in a Big Way Regarding M&A

While presenting at the J.P. Morgan Healthcare Conference, CEO Alex Gorsky laid out critical details to J&J's acquisition strategy.

Geron: What To Expect From Imetelstat Now

Monday's ETF with Unusual Volume: DWAS

No JP Morgan Conference Love for Ionis Pharmaceuticals Inc, Geron Corporation, and Medivation Inc

Apparently, no news is bad news.

Geron Corporation Exploded 49% Higher in 2015 -- Here's Why

The promise of Geron's lead experimental drug sent its shares notably higher last year, but can the good times continue in 2016?

Geron (GERN) Is Strong On High Volume Today

See More Articles...